MX2021010595A - Composicion farmaceutica, preparacion y usos de la misma. - Google Patents

Composicion farmaceutica, preparacion y usos de la misma.

Info

Publication number
MX2021010595A
MX2021010595A MX2021010595A MX2021010595A MX2021010595A MX 2021010595 A MX2021010595 A MX 2021010595A MX 2021010595 A MX2021010595 A MX 2021010595A MX 2021010595 A MX2021010595 A MX 2021010595A MX 2021010595 A MX2021010595 A MX 2021010595A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compound
carrier
biocompatible nanoparticle
subject
need
Prior art date
Application number
MX2021010595A
Other languages
English (en)
Inventor
Laurent Levy
Agnès Pottier
Matthieu Germain
Marie- Edith Meyre
Original Assignee
Curadigm Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curadigm Sas filed Critical Curadigm Sas
Publication of MX2021010595A publication Critical patent/MX2021010595A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende la combinación de (i) al menos una nanopartícula biocompatible y de (ii) al menos un vehículo que comprende al menos un compuesto farmacéutico, para administración a un sujeto que precisa dicho compuesto farmacéutico, en donde la combinación de la al menos una nanopartícula biocompatible y el al menos un vehículo que comprende el(los) compuesto(s) farmacéutico(s) potencia el(los) compuesto(s) de eficacia de interés. La dimensión más larga de la nanopartícula biocompatible está normalmente entre aproximadamente 4 y aproximadamente 500 nm y su valor absoluto de carga superficial es de al menos 10 mV (|10 mV|). El vehículo además está desprovisto de cualquier agente estéricamente estabilizador de superficie. La invención también se refiere a dicha composición para su uso en la administración del(de los) compuesto(s) farmacéutico(s) en un sujeto que lo precisa, en donde la al menos una nanopartícula biocompatible y el al menos un vehículo que comprende el al menos un compuesto farmacéutico se administran por separado en un sujeto que necesita dicho compuesto farmacéutico, normalmente entre más de 5 minutos y aproximadamente 72 horas uno con respecto a otro.
MX2021010595A 2014-11-25 2017-05-24 Composicion farmaceutica, preparacion y usos de la misma. MX2021010595A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14306875 2014-11-25

Publications (1)

Publication Number Publication Date
MX2021010595A true MX2021010595A (es) 2021-09-23

Family

ID=52013982

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006812A MX2017006812A (es) 2014-11-25 2015-11-24 Composición farmacéutica, preparación y usos de la misma.
MX2021010595A MX2021010595A (es) 2014-11-25 2017-05-24 Composicion farmaceutica, preparacion y usos de la misma.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017006812A MX2017006812A (es) 2014-11-25 2015-11-24 Composición farmacéutica, preparación y usos de la misma.

Country Status (17)

Country Link
US (1) US10765632B2 (es)
EP (1) EP3236934B1 (es)
JP (1) JP6789960B2 (es)
CN (1) CN107106703A (es)
AR (1) AR102782A1 (es)
AU (1) AU2015352685B2 (es)
BR (1) BR112017010953B1 (es)
CA (1) CA2968919C (es)
EA (1) EA201791147A1 (es)
HK (1) HK1245085A1 (es)
IL (2) IL252462B (es)
MX (2) MX2017006812A (es)
NZ (1) NZ769187A (es)
SG (1) SG11201704219UA (es)
TW (1) TW201628656A (es)
UA (1) UA123665C2 (es)
WO (1) WO2016083333A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509436TA (en) * 2013-05-30 2015-12-30 Nanobiotix Pharmaceutical composition, preparation and uses thereof
LT3223796T (lt) 2014-11-25 2021-10-25 Curadigm Sas Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai
LT3229776T (lt) 2014-11-25 2023-08-25 Curadigm Sas Farmacinė kompozicija, kurioje derinamos mažiausiai dvi skirtingos nanodalelės ir farmacinis mišinys, jos paruošimas ir vartojimas
PL3229843T3 (pl) 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
CN107708668A (zh) 2015-05-28 2018-02-16 纳米生物技术公司 用作治疗性疫苗的纳米粒子

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
CA2547024C (en) 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
CA2555343A1 (en) * 2004-02-10 2005-09-22 Barnes-Jewish Hospital Improved efficacy and safety of targeted particulate agents with decoy systems
US20060264804A1 (en) * 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
US20070088414A1 (en) * 2005-05-25 2007-04-19 Campbell Robert L Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
EP2000150B1 (en) 2006-03-24 2016-07-13 Toto Ltd. Titanium oxide complex particle, dispersion solution of the particle, and process for production of the particle
WO2007116954A2 (en) 2006-03-30 2007-10-18 Fujifilm Corporation Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
WO2007128066A1 (en) 2006-05-04 2007-11-15 University Of South Australia Drug release from nanoparticle-coated capsules
KR20100095507A (ko) * 2007-08-21 2010-08-31 알자 코퍼레이션 보론산 화합물의 생체내 투여를 위한 리포좀 조성물
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
WO2009081287A2 (en) 2007-12-21 2009-07-02 University Of Guelph Polysaccharide nanoparticles
EP2280601A4 (en) 2008-02-21 2012-08-29 Sequoia Pharmaceuticals Inc AMINO ACID HEMMER OF CYTOCHROM P450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
WO2011102407A1 (ja) 2010-02-17 2011-08-25 国立大学法人神戸大学 放射線治療剤
PT2552438T (pt) 2010-03-26 2016-07-07 Abraxis Bioscience Llc Métodos de tratamento de carcinoma hepatocelular
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
US9782342B2 (en) 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
CA2825564A1 (en) * 2011-01-31 2012-08-09 Nanobiotix Nanoparticles delivery systems, preparation and uses thereof
JP2014503575A (ja) * 2011-01-31 2014-02-13 ナノビオティックス 超常磁性のナノ粒子を用いて、興味対象生成物のリポソームからの放出をモニターする方法
WO2013059295A2 (en) 2011-10-17 2013-04-25 Trustees Of Boston University Polymeric depots for localization of an agent to biological sites
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
SG11201509436TA (en) 2013-05-30 2015-12-30 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
LT3229776T (lt) 2014-11-25 2023-08-25 Curadigm Sas Farmacinė kompozicija, kurioje derinamos mažiausiai dvi skirtingos nanodalelės ir farmacinis mišinys, jos paruošimas ir vartojimas
PL3229843T3 (pl) 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
KR20170086638A (ko) 2014-11-25 2017-07-26 나노비오?스 약학 조성물, 이의 제조 및 용도
LT3223796T (lt) 2014-11-25 2021-10-25 Curadigm Sas Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai

Also Published As

Publication number Publication date
IL290114A (en) 2022-03-01
IL252462B (en) 2022-03-01
AU2015352685A1 (en) 2017-07-13
EA201791147A1 (ru) 2017-11-30
AR102782A1 (es) 2017-03-22
MX2017006812A (es) 2018-02-12
CN107106703A (zh) 2017-08-29
AU2015352685B2 (en) 2020-09-17
IL252462A0 (en) 2017-07-31
SG11201704219UA (en) 2017-06-29
CA2968919A1 (en) 2016-06-02
EP3236934A1 (en) 2017-11-01
BR112017010953B1 (pt) 2024-01-16
TW201628656A (zh) 2016-08-16
NZ732995A (en) 2021-01-29
UA123665C2 (uk) 2021-05-12
HK1245085A1 (zh) 2018-08-24
JP2017538783A (ja) 2017-12-28
WO2016083333A1 (en) 2016-06-02
JP6789960B2 (ja) 2020-11-25
US20170258721A1 (en) 2017-09-14
EP3236934B1 (en) 2024-05-22
CA2968919C (en) 2023-07-18
US10765632B2 (en) 2020-09-08
NZ769187A (en) 2023-07-28
KR20170093860A (ko) 2017-08-16
BR112017010953A2 (pt) 2018-02-14

Similar Documents

Publication Publication Date Title
NZ714273A (en) Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
MX2021010595A (es) Composicion farmaceutica, preparacion y usos de la misma.
MX2017006813A (es) Composicion farmaceutica, preparacion y usos de la misma.
MX2023000745A (es) Composiciones para usarse en el suministro de agentes biomacromoleculares.
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
MX2019007187A (es) Composiciones para el cuidado bucal.
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
WO2015023691A3 (en) 4-methylumbelliferone treatment for immune modulation
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
MY173573A (en) Pyridin-4-yl derivatives
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2017016231A (es) Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
SG10201907289VA (en) Monomethylfumarate prodrug compositions
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
WO2016040814A3 (en) Disulfide polymers and methods of use
MX2019007361A (es) Composiciones para el cuidado bucal.
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2015011588A (es) Tratamiento de combinacion.
IN2013MU01177A (es)